<DOC>
	<DOCNO>NCT03100864</DOCNO>
	<brief_summary>The primary objective trial understand mechanism action BI655130 patient UC Secondary objective explore clinical effect , safety tolerability ( include immunogenicity ) BI 655130 treatment</brief_summary>
	<brief_title>This Study Tests How BI 655130 Works Patients With Active Ulcerative Colitis . The Study Also Tests How Well BI 655130 Tolerated Whether Helps Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>18 65 year screen Diagnosis UC &gt; = 3 month prior screen . Moderately severely active UC confirm Mayo Score â‰¥6 Receiving conventional , nonbiologic therapy UC . Negative colon cancer screen Further inclusion criterion apply Prior use biological treatment past ( e.g . TNFa integrin inhibitor , investigational biological drug ) Extensive colonic resection Evidence infection C. difficile intestinal pathogen &lt; 30 day prior screen Active latent tuberculosis Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>